ADMA Biologics (NASDAQ:ADMA - Get Free Report) had its target price lifted by stock analysts at HC Wainwright from $18.00 to $26.00 in a research report issued on Friday,Benzinga reports. The brokerage presently has a "buy" rating on the biotechnology company's stock. HC Wainwright's target price indicates a potential upside of 14.94% from the stock's current price. HC Wainwright also issued estimates for ADMA Biologics' Q4 2024 earnings at $0.19 EPS, FY2024 earnings at $0.55 EPS, Q1 2025 earnings at $0.20 EPS, Q2 2025 earnings at $0.21 EPS, Q3 2025 earnings at $0.22 EPS and Q4 2025 earnings at $0.24 EPS.
A number of other equities research analysts have also weighed in on the stock. Cantor Fitzgerald restated an "overweight" rating and issued a $20.00 target price on shares of ADMA Biologics in a report on Friday, September 20th. Raymond James increased their price objective on ADMA Biologics from $18.00 to $25.00 and gave the stock a "strong-buy" rating in a research note on Friday. One analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, ADMA Biologics presently has an average rating of "Buy" and an average price target of $21.25.
Get Our Latest Analysis on ADMA
ADMA Biologics Stock Up 14.7 %
ADMA Biologics stock traded up $2.90 during mid-day trading on Friday, reaching $22.62. The stock had a trading volume of 9,717,443 shares, compared to its average volume of 3,667,173. The firm has a market capitalization of $5.27 billion, a PE ratio of 80.79 and a beta of 0.64. ADMA Biologics has a fifty-two week low of $3.60 and a fifty-two week high of $23.52. The stock's 50-day simple moving average is $18.12 and its 200-day simple moving average is $13.89. The company has a debt-to-equity ratio of 0.74, a quick ratio of 2.80 and a current ratio of 6.87.
ADMA Biologics (NASDAQ:ADMA - Get Free Report) last announced its quarterly earnings results on Thursday, August 8th. The biotechnology company reported $0.13 EPS for the quarter, beating analysts' consensus estimates of $0.08 by $0.05. ADMA Biologics had a net margin of 10.53% and a return on equity of 38.79%. The business had revenue of $107.20 million during the quarter, compared to analyst estimates of $86.44 million. During the same quarter in the previous year, the business posted ($0.02) EPS. ADMA Biologics's quarterly revenue was up 78.4% on a year-over-year basis. On average, sell-side analysts forecast that ADMA Biologics will post 0.49 EPS for the current fiscal year.
Insider Buying and Selling
In other ADMA Biologics news, Director Lawrence P. Guiheen sold 9,000 shares of the stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $18.47, for a total value of $166,230.00. Following the completion of the sale, the director now owns 153,941 shares in the company, valued at approximately $2,843,290.27. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, Director Lawrence P. Guiheen sold 9,000 shares of the stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $18.47, for a total transaction of $166,230.00. Following the completion of the sale, the director now directly owns 153,941 shares of the company's stock, valued at approximately $2,843,290.27. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Adam S. Grossman sold 236,889 shares of the company's stock in a transaction on Monday, August 26th. The shares were sold at an average price of $17.69, for a total value of $4,190,566.41. Following the completion of the transaction, the chief executive officer now owns 2,059,726 shares of the company's stock, valued at $36,436,552.94. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 466,900 shares of company stock worth $8,224,121. 3.70% of the stock is owned by insiders.
Institutional Trading of ADMA Biologics
Hedge funds have recently added to or reduced their stakes in the stock. D. E. Shaw & Co. Inc. increased its stake in shares of ADMA Biologics by 26.8% during the 2nd quarter. D. E. Shaw & Co. Inc. now owns 6,824,517 shares of the biotechnology company's stock worth $76,298,000 after purchasing an additional 1,442,799 shares during the last quarter. Assenagon Asset Management S.A. increased its position in ADMA Biologics by 2.7% in the third quarter. Assenagon Asset Management S.A. now owns 3,474,455 shares of the biotechnology company's stock worth $69,454,000 after buying an additional 92,281 shares during the last quarter. Driehaus Capital Management LLC raised its stake in shares of ADMA Biologics by 17.3% in the second quarter. Driehaus Capital Management LLC now owns 3,028,667 shares of the biotechnology company's stock valued at $33,860,000 after buying an additional 447,743 shares during the period. Renaissance Technologies LLC lifted its position in shares of ADMA Biologics by 28.7% during the 2nd quarter. Renaissance Technologies LLC now owns 2,582,135 shares of the biotechnology company's stock valued at $28,868,000 after buying an additional 575,100 shares during the last quarter. Finally, Federated Hermes Inc. grew its stake in shares of ADMA Biologics by 15.5% during the 2nd quarter. Federated Hermes Inc. now owns 1,969,811 shares of the biotechnology company's stock worth $22,022,000 after acquiring an additional 263,677 shares during the period. Institutional investors own 75.68% of the company's stock.
About ADMA Biologics
(
Get Free Report)
ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.
See Also
Before you consider ADMA Biologics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ADMA Biologics wasn't on the list.
While ADMA Biologics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
